PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33790106-0 2021 The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFalpha Antibody in a Mouse Colitis Model. Tacrolimus 20-30 tumor necrosis factor Mus musculus 67-75 33790106-2 2021 However, the optimal dose of TAC in combination therapy with anti-TNFalpha antibodies (TAC + anti-TNFalpha therapy) remains unclear. Tacrolimus 29-32 tumor necrosis factor Mus musculus 98-106 25491293-8 2014 The gene expression of IL-1beta and TNF-alpha in the FK-506 and vehicle-treated groups were 47.01% and 45.56%, 85.91% and 115.83% of that in the saline-treated group in the ocular surface, while in the lacrimal glands 49.16% and 67.60%, 94.91% and 95.77% of that in the saline-treated group, respectively. Tacrolimus 53-59 tumor necrosis factor Mus musculus 36-45 33790106-10 2021 The serum concentration of anti-TNFalpha antibodies in the high-dose TAC + anti-TNFalpha therapy was significantly higher than those in the other groups. Tacrolimus 69-72 tumor necrosis factor Mus musculus 32-40 33790106-11 2021 Low-dose TAC exerted its immunosuppressive effect on T-cells, and additionally, high-dose TAC maintained the serum anti-TNFalpha antibody concentration. Tacrolimus 90-93 tumor necrosis factor Mus musculus 120-128 33790106-12 2021 When administered in combination with anti-TNFalpha antibodies, the dose of TAC should be adjusted according to the disease severity. Tacrolimus 76-79 tumor necrosis factor Mus musculus 43-51 32563057-6 2020 Systemic MDSC plus FK-506 therapy was found to have a significant anti-psoriatic effect in the murine model, to reduce levels of pro-inflammatory cytokines Th1 cytokines (TNF-alpha and IFN-gamma) and Th17 cytokines (IL-17A and IL-23) in serum and skin. Tacrolimus 19-25 tumor necrosis factor Mus musculus 171-180 26198442-5 2015 OBJECTIVE: To investigate whether the glucocorticosteroid dexamethasone and the calcineurin inhibitor tacrolimus could affect TSLP expression induced by TNF-alpha in lesional keratinocytes of AD. Tacrolimus 102-112 tumor necrosis factor Mus musculus 153-162 32060883-3 2020 Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-alpha. Tacrolimus 51-54 tumor necrosis factor Mus musculus 119-128 28522399-7 2017 Sacran solutions and 0.1%Tacrolimus reduced disease severity, suppressed histological changes and decreased the serum Th-1 (IFN-gamma, TNF-alpha, IL-2) and Th-2 (IL-4, IL-6, IL-10) cytokines in allergic mice (vs. controls). Tacrolimus 25-35 tumor necrosis factor Mus musculus 135-144 24041534-8 2013 Moreover, TNF-alpha significantly enhanced apoptotic cell death induced by cisplatin, cyclosporine A, tacrolimus and azidothymidine. Tacrolimus 102-112 tumor necrosis factor Mus musculus 10-19 25464008-9 2014 In contrast, FK506 reduced the expression of TREM-1, IL-1beta and TNFalpha in RAW264.7 macrophages stimulated with zymosan. Tacrolimus 13-18 tumor necrosis factor Mus musculus 66-74 15153522-8 2004 As a downstream of calpain, calcineurin was activated and the inhibition of calcineurin activation by FK506 diminished insulinoma cell death by IFN-gamma/TNF-alpha. Tacrolimus 102-107 tumor necrosis factor Mus musculus 154-163 23032068-4 2012 The effect of FK506 treatment (10 mug per eye for one week) was evaluated by TNF-a, VEGF, iNOS and COX-2 protein levels measurement, neovascularization, and the activation of NF-kB in the retina. Tacrolimus 14-19 tumor necrosis factor Mus musculus 77-82 23032068-6 2012 FK506 treatment significantly lowered retinal TNF-a, VEGF, iNOS and COX-2. Tacrolimus 0-5 tumor necrosis factor Mus musculus 46-51 19454717-7 2009 In TNF-alpha-treated cells, suppression of MCP-1 by CsA or FK506 was associated with blunted responses of NF-kappaB, the crucial regulator of MCP-1. Tacrolimus 59-64 tumor necrosis factor Mus musculus 3-12 19454717-9 2009 CsA and FK506, as well as other UPR inducers, caused up-regulation of C/EBP family members, especially C/EBPbeta and CHOP (C/EBP homologous protein), and overexpression of either C/EBPbeta or CHOP significantly attenuated TNF-alpha-triggered NF-kappaB activation. Tacrolimus 8-13 tumor necrosis factor Mus musculus 222-231 17522069-7 2007 This conclusion was based on the findings that inhibition of NFAT3 activation by either FK506 or NFAT3 siRNA dramatically down-regulated the TNF induction upon B[a]PDE exposure, and that knock-down of TNF by its specific siRNA also led to abrogation of B[a]PDE-induced cell transformation in Cl41 cells and their tumorigenicity in nude mice. Tacrolimus 88-93 tumor necrosis factor Mus musculus 141-144 17304209-7 2007 Inhibition of the expression of TNF-alpha and MMP9 by the anti-inflammatory reagent FK506 could cure the epidermal hyperplasia, suggesting a causal link between inflammation and epidermal hyperplasia. Tacrolimus 84-89 tumor necrosis factor Mus musculus 32-41 15948987-9 2005 Both RT-PCR and immunohistochemical staining of sections from ear biopsies demonstrated that nanocrystalline silver, tacrolimus and steroid significantly suppressed the expression of tumour necrosis factor (TNF)-alpha and interleukin (IL)-12. Tacrolimus 117-127 tumor necrosis factor Mus musculus 183-217 21830095-7 2011 Tacrolimus completely inhibited IFN-gamma and TNF-alpha production of activated T-cells in LPMCs, but only partially inhibited IFN-gamma, TNF-alpha, and IL-12 production of activated monocytes/macrophages in LPMCs. Tacrolimus 0-10 tumor necrosis factor Mus musculus 46-55 21830095-7 2011 Tacrolimus completely inhibited IFN-gamma and TNF-alpha production of activated T-cells in LPMCs, but only partially inhibited IFN-gamma, TNF-alpha, and IL-12 production of activated monocytes/macrophages in LPMCs. Tacrolimus 0-10 tumor necrosis factor Mus musculus 138-147 18346634-12 2008 On the other hand, tacrolimus and dexamethasone, but not indomethacin, decreased TNF-alpha levels (P<0.01). Tacrolimus 19-29 tumor necrosis factor Mus musculus 81-90 17878357-4 2007 We further found that IkappaB-alpha degradation, MAPK activation, and TNF-alpha production by FK506 were reduced in macrophages from mice deficient in MyD88, Toll/IL-1R domain-containing adaptor-inducing IFN-beta (TRIF), TLR2, or TLR4, whereas macrophages from TLR3-deficient or TLR9 mutant mice showed the same responses to FK506 as those of wild-type cells. Tacrolimus 94-99 tumor necrosis factor Mus musculus 70-79 16860713-2 2006 OBJECTIVES: This study evaluated whether the acute and systemic administration of Tacrolimus significantly interfered in leukocyte migration, exudation, myeloperoxidase and adenosine-deaminase and nitric oxide levels, as well as Interleukin-1 (IL-1beta) and tumor necrosis factor alpha (TNFalpha) levels in a mouse model of pleurisy in comparison to those obtained with dexamethasone. Tacrolimus 82-92 tumor necrosis factor Mus musculus 258-285 16860713-2 2006 OBJECTIVES: This study evaluated whether the acute and systemic administration of Tacrolimus significantly interfered in leukocyte migration, exudation, myeloperoxidase and adenosine-deaminase and nitric oxide levels, as well as Interleukin-1 (IL-1beta) and tumor necrosis factor alpha (TNFalpha) levels in a mouse model of pleurisy in comparison to those obtained with dexamethasone. Tacrolimus 82-92 tumor necrosis factor Mus musculus 287-295 15153522-9 2004 BAD phosphorylation was decreased by IFN-gamma/TNF-alpha because of the increased calcineurin activity, which was reversed by FK506. Tacrolimus 126-131 tumor necrosis factor Mus musculus 47-56 9462649-7 1998 Complete obliteration of hemostasis and hepatic injury was also accomplished by the pretreatment with FK506 which suppressed TNF-alpha and IFN-gamma production. Tacrolimus 102-107 tumor necrosis factor Mus musculus 125-134 12100723-9 2002 FK506, a calcineurin inhibitor, and nifedipine, a calcium channel inhibitor, inhibited not only the expression of TNF-alpha and CD40L, but also the up-regulation of CD80 on irradiated A20-HL cells. Tacrolimus 0-5 tumor necrosis factor Mus musculus 114-123 8890921-3 1996 It has been shown that glucocorticoids and immunosuppressive agents such as cyclosporin and FK-506 inhibit TNF-alpha generation by T-lymphocytes and monocytes. Tacrolimus 92-98 tumor necrosis factor Mus musculus 107-116 34875338-14 2022 Finally, we found that FK506 pretreatment ameliorated the neurite growth in neurons treated with TNF and the learning ability of mice after surgery. Tacrolimus 23-28 tumor necrosis factor Mus musculus 97-100 7530743-5 1995 The IC50 value for FK506 inhibition of IgE activation-induced transcripts for TNF-alpha decreased from 40 nM in vector control cells to 10 nM in FKBP12 transfectants. Tacrolimus 19-24 tumor necrosis factor Mus musculus 78-87 7530743-8 1995 Thus, FKBP12 is the dominant cytosolic protein that mediates FK506 inhibition of TNF-alpha and IL-6 transcripts. Tacrolimus 61-66 tumor necrosis factor Mus musculus 81-90 34217824-5 2021 FK506@EHCh NPs significantly suppressed secretion of TNF-alpha, IL-1beta and IL-6 by LPS-activated Raw 264.7 macrophages. Tacrolimus 0-5 tumor necrosis factor Mus musculus 53-62